Cirrhosis
Conditions
Keywords
Decompensation of cirrhosis, Iron metabolism
Brief summary
Iron is a crucial metal whose metabolism is tightly regulated. Iron deficiency or iron overload are both deleterious at the cellular, organic and systemic levels. In line with the major role of the liver in iron homeostasis, links between iron metabolism and acute on chronic liver failure have been highlighted. Nevertheless, due to the difficulty of accurately assessing iron metabolism in this situation, therapeutic intervention on iron metabolism in this setting is currently not codified. A better understanding of these mechanisms is therefore essential, in particular by characterizing the impact of exposure to non-transferrin-bound iron in acute on chronic liver failure on short-term mortality. Overall, a better understanding of the physiopathological mechanisms of iron should allow to optimize the martial balance in this condition and also improve therapeutic approaches.
Interventions
BIOLOGICALblood sampling
blood sampling
Sponsors
Rennes University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old. * Diagnosis of cirrhosis, previously known or not, of any etiology, histologically proven or not. * Hospitalization for acute on chronic liver failure: * Ascites decompensation. * Or spontaneous infection of the ascites fluid (defined as PNN \> 250/mm3 of ascites). * Or digestive hemorrhage related to portal hypertension (digestive fibroscopy showing active bleeding or stigmas of recent bleeding from esophageal and/or gastric varices). * Or hepatic encephalopathy (clinically defined +/- increase in ammonia and/or by electroencephalogram and classified in stages according to West-Haven). * Or hepato-renal syndrome (HRS-AKI criteria, EASL 2018). * Or bacterial infection (defined by a bacteremia identified by at least one blood culture and/or an infectious site authenticated on imaging). * Or Acute Alcoholic Hepatitis (histologically proven or not). * Non-opposition of the patient, relative or legal representative.
Exclusion criteria
* Treatment with oral or intravenous iron in the month prior to hospitalization. * Implementation of a TIPS in the month prior to admission. * Presence of hepatocellular carcinoma with an expected survival \< 3 months or any other progressive cancer. * Adult person subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of abnormal iron | days 0, 2, 7 and 14 |
| Ceruloplasmin ferroxidase activity | days 0, 2, 7 and 14 |
| hepcidin blood levels | days 0, 2, 7 and 14 |
| Ferritinemia | days 0, 2, 7 and 14 |
| transferrinemia | days 0, 2, 7 and 14 |
| transferrin saturation coefficient | days 0, 2, 7 and 14 |
| Blood levels of manganese | days 0, 2, 7 and 14 |
| Occurrence of complications | during hospitalization and a maximum of 28 days after admission |
| Bacterial infection | during hospitalization and a maximum of 28 days after admission |
| fungal infection | during hospitalization and a maximum of 28 days after admission |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORGiguet Baptiste
Rennes University Hospital
Outcome results
None listed